In the Claims

- (currently amended) A vaccine composition for cancer immunotherapy comprising a
 monoclonal antibody directed to a cancer cell and transfer factor wherein the
 monoclonal antibody is conjugated to an a fungal antigen or mumps virus.
- 2. (currently amended) The vaccine composition according to claim 1 wherein the cancer cell monoclonal antibody is directed to a predetermined type of cell that is in a bodypart selected from the group consisting of lung, pancreas, liver, cervical cervix, kidney, brain, and breast and spleen cancers.
- (currently amended) The vaccine composition according to claim 2 wherein the cancer cell is monoclonal antibody is directed to a predetermined type of cells in a pancreas cancer cell.
- 4. (currently amended) The vaccine composition according to claim 1 wherein the <u>fungal</u> antigen is asp f1.
- 5. (canceled) The vaccine according to claim 1 wherein the antigen is the mumps virus.
- (currently amended) The vaccine composition according to claim 1 wherein the
 monoclonal antibody is selected from the group consisting of 17-1A, CC49, EGFr
 surface factor, anti MC-10 antigen, anti-HER2, anti-CD20, NR-LU-10 and MDX-H210.
- 7. (withdrawn) An anti-cancer vaccine comprising a virus and transfer factor wherein the virus infects cancer cells, wherein the virus further includes an antigen.
- 8. (withdrawn) The vaccine according to claim 7 wherein the virus is selected from the group consisting of mumps, hepatitis encephalitis, Varicilla, Rubella and measles.
- 9. (withdrawn) The vaccine according to claim 8 wherein the virus is the mumps virus.
- 10. (withdrawn) The vaccine according to claim 7 wherein the antigen is asp fl.
- 11. (withdrawn) A method of treating cancer comprising:

- a) preparing a vaccine according to claim 1 and
- b) administering the vaccine.
- 12. (currently amended) A <u>method of applying the</u> composition comprising the vaccine of claim 1, for use in a method of treatment of cancer in a human body; said method comprising:
 - administering to said human said monoclonal antibody to a human being; and administering said transfer factor to the human being in a separate step steps.
- 13. (withdrawn) A composition comprising the vaccine of claim 7 for use in the treatment of cancer in a human body said method comprising administering to said human said virus and said transfer factor in separate steps.
- 14. (withdrawn) A cancer immunotherapy composition comprising a virus wherein the virus further includes an antigen and wherein the virus infects cancer cells.
- 15. (withdrawn) The composition according to claim 14 wherein the virus is the mumps virus.
- 16. (withdrawn) The composition according to claim 17 further including transfer factor.
- 17. (withdrawn) A cancer immunotherapy kit comprising a virus that infects cancer cells, wherein the virus further includes an antigen.
- 18. (withdrawn) The kit according to claim 18 further including transfer factor.
- 19. (withdrawn) The kit according to claim 18 wherein the virus is the mumps virus.
- 20. (currently amended) A cancer immunotherapy kit comprising a monoclonal antibody and transfer factor wherein the monoclonal antibody further includes an is conjugated to a fungal antigen and transfer factor or mumps virus.
- 21. (currently amended) The kit according to claim 24 20 wherein the <u>fungal</u> antigen is asp f1.

- 22. (new) The composition of claim 1, wherein the fungal antigen is an aspergillus antigen.
- 23. (new) The kit of claim 20, wherein the fungal antigen is an aspergillus antigen.